Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women
- First Posted Date
- 2010-04-09
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Amgen
- Target Recruit Count
- 31
- Registration Number
- NCT01101061
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2010-03-04
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 792
- Registration Number
- NCT01080391
- Locations
- 🇺🇸
Providence St. Joseph Medical Center, Burbank, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 4509
- Registration Number
- NCT01077154
- Locations
- 🇬🇧
Research Site, Truro, United Kingdom
A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Postmenopausal Women
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 74
- Registration Number
- NCT01059435
Safety and Efficacy of AMG 827 in Subjects With RA
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 211
- Registration Number
- NCT01059448
- Locations
- 🇬🇧
Research Site, Merseyside, United Kingdom
AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 397
- Registration Number
- NCT01018550
Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis
- Conditions
- Interventions
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 43
- Registration Number
- NCT01000961
- Locations
- 🇫🇷
Villeneuve-Lapeyronie Hospital, Montpellier, France
🇺🇸Stanford University Medical School, Stanford, California, United States
🇳🇱Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 46
- Registration Number
- NCT00992459
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Maine Medical Center, Portland, Maine, United States
🇺🇸SNBL-Clinical Pharmacology Center, Baltimore, Maryland, United States
Darbepoetin Alfa and Anemia of Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 287
- Registration Number
- NCT00989092
Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment
- Conditions
- Interventions
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 86
- Registration Number
- NCT00984815
- Locations
- 🇺🇸
Altoona Center for Clinical Research Altoona Arthritis, Duncansville, Pennsylvania, United States
🇺🇸Illinois Bone & Joint Institute, Morton Grove, Illinois, United States
🇺🇸Metroplex Clinical Research Center, Dallas, Texas, United States